Nε-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease

Free Radical Biology and Medicine

Volumn 36, Issue 10, 2004, Pages 1241-1247

  Gironès, Xavier ^a   Guimerà, Arantxa ^a   Cruz Sánchez, Celia Z ^a   Ortega, Arantxa ^b   Sasaki, Noboyuki ^c   Makita, Zenji ^d   Lafuente, José Vivente ^e   Kalaria, Raj ^f   Cruz Sánchez, Félix F ^a  

^a UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^b Department of Pathology   (Spain)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d KURUME UNIVERSITY   (Japan)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Advanced glycation end products; Aging; Alzheimer's disease; Diabetes mellitus; Free radicals; Glycation; Hippocampus; Microangiopathy

Indexed keywords

AMYLOID BETA PROTEIN; CARBOXYL GROUP; LYSINE DERIVATIVE; METHYL GROUP; ADVANCED GLYCATION END PRODUCT; DRUG DERIVATIVE; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN SLICE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FRONTAL CORTEX; GLIA CELL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MOLECULAR DYNAMICS; NERVE CELL; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TEMPORAL CORTEX; TOPOGRAPHY; BRAIN; CYTOLOGY; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN; CYTOPLASM; DIABETES MELLITUS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; NEURONS; SENILE PLAQUES; TAU PROTEINS;

EID: 1942520335     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.02.006     Document Type: Article

References (24)

1. Sasaki N., Toki S., Chowei H., Saito T., Nakano N., Hayashi Y., Takeuchi M., Makita Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888:2001;256-262.
2. Wong A., Luth H.J., Deuther-Conrad W., Dukic-Stefanovic S., Gasic-Milenkovic J., Arendt T., Münch G. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res. 920:2001;32-40.
3. Takeuchi M., Bucala R., Suzuki T., Ohkubo T., Yamazaki M., Koike T., Kameda Y., Makita Z. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59:2000;1094-1105.
4. Schmidt A.M., Yan S.D., Wautier J.-L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84:1998;489-497.
5. Kalaria R.N. Cerebral vessels in ageing and Alzheimer's disease. (review) Pharmacol. Ther. 72:1996;193-214.
6. Aliev G., Smith M.A., Seyidov D., Neal M.L., Lamb B.T., Nunomura A., Gasimov E.K., Vinters H.V., Perry G., LaManna J.C., Friedland R.P. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. 12:2002;21-35.
7. Dei R., Takeda A., Niwa H., Li M., Nakagomi Y., Watanabe M., Inagaki T., Washimi Y., Yasuda Y., Horie K., Miyata T., Sobue G. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol. 104:2002;113-122.
8. Li J.J., Dickson D.W., Hof P.R., Vlassara H. Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Mol. Med. 4:1998;46-60.
9. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflamatory responses. Circulation. 105:2002;816-822.
10. Takeuchi M., Makita Z., Yanagisawa K., Kameda Y., Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5:1999;393-405.
11. Smith M.A., Monnier V.M., Sayre L.M., Perry G. Amyloidosis, advanced glycation end products and Alzheimer disease. NeuroReport. 6:1995;1595-1596.
12. Cruz-Sánchez F.F., Marin C., Rossi M.L., Cardozo A., Ferrer I., Tolosa E. Ubiquitin in cerebral amyloid angiopathy. Neurol. Sci. 112:1992;46-50.
13. Martin L.J., Pardo C.A., Cork L.C., Price D.L. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am. J. Pathol. 145:1994;1358-1381.
14. Soininen H., Heinonen H., Sorvari H., Kosunene O., Paljarvi L., Koivisto E., Riekkinen P.J. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenom in Alzheimer's disease. Neuroscience. 64:1995;375-384.
15. Di Patre P.L., Read S.L., Cummings J.L., Tomiyasu U., Vartavarian L.M., Secor D.L., Vinters H.V. Progression of clinical deterioration and pathological changes in patients with Alzheimer's disease evaluated at biopsy and autopsy. Arch. Neurol. 56:1999;1254-1261.
16. Cruz-Sánchez F.F., Moral A., Tolosa E., Belleroche J., Rossi M.L. Evaluation of neuronal loss, astrocytosis and abnormalities of cytoskeletal components of large motoneurons in the human anterior horn in aging. J. Neural. Transm. 105:1998;689-701.
17. Thornalley P.J. Glycation in diabetic neuropathy: characteristics, consequences, causes and therapeutic options. Int. Rev. Neurobiol. 50:2002;37-57.
18. Stitt A.W., Burke G.A., Chen F., Mcmullen C.B.T., Vlassara H. Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J. 14:2000;2390-2392.
19. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272:1997;17810-17814.
20. Yan S.D., Stern D., Schmidt A.M. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur. J. Clin. Invest. 27:1997;179-181.
21. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end- products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6:2000;114-125.
22. Lue L.-F., Walker D., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D. Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171:2001;29-45.
23. Nishino T., Horii Y., Shiiki H., Yamamoto H., Makita Z., Bucala R., Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum. Pathol. 26:1995;308-313.
24. Heitner J., Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. Neurology. 49:1997;1306-1311.